Unknown

Dataset Information

0

Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML.

ABSTRACT: Allogeneic hematopoietic cell transplantation (HCT) is often unsuccessful for monosomal karyotype (MK) acute myeloid leukemia (AML). To what degree failures are associated with pretransplant measurable residual disease (MRD)-a dominant adverse-risk factor-is unknown. We therefore studied 606 adults with intermediate- or adverse-risk AML in morphologic remission who underwent allogeneic HCT between 4/2006 and 1/2019. Sixty-eight (11%) patients had MK AML, the majority of whom with complex cytogenetics. Before HCT, MK AML patients more often tested MRDpos by multiparameter flow cytometry (49 vs. 18%; P?

SUBMITTER: Morsink LM 

PROVIDER: S-EPMC7272254 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML.

Morsink Linde M LM   Othus Megan M   Bezerra Evandro D ED   Wood Brent L BL   Fang Min M   Sandmaier Brenda M BM   Mielcarek Marco M   Schoch Gary G   Storb Rainer R   Deeg H Joachim HJ   Appelbaum Frederick R FR   Walter Roland B RB  

Leukemia 20200123 6

Allogeneic hematopoietic cell transplantation (HCT) is often unsuccessful for monosomal karyotype (MK) acute myeloid leukemia (AML). To what degree failures are associated with pretransplant measurable residual disease (MRD)-a dominant adverse-risk factor-is unknown. We therefore studied 606 adults with intermediate- or adverse-risk AML in morphologic remission who underwent allogeneic HCT between 4/2006 and 1/2019. Sixty-eight (11%) patients had MK AML, the majority of whom with complex cytogen  ...[more]

Similar Datasets

Unknown Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
| S-EPMC7116653 | biostudies-literature
Unknown Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies.
| S-EPMC4716890 | biostudies-literature
Unknown Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
| S-EPMC8616076 | biostudies-literature
Unknown Monosomal karyotype at the time of diagnosis or transplantation predicts outcomes of allogeneic hematopoietic cell transplantation in myelodysplastic syndrome.
| S-EPMC4790415 | biostudies-literature
Unknown Monitoring of Measurable Residual Disease Using Circulating DNA after Allogeneic Hematopoietic Cell Transplantation.
| S-EPMC9323743 | biostudies-literature
Unknown Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation.
| S-EPMC3156042 | biostudies-literature
Unknown Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype.
| S-EPMC6545848 | biostudies-literature
Unknown Genotype-outcome correlations in pediatric AML: the impact of a monosomal karyotype in trial AML-BFM 2004.
| S-EPMC5729330 | biostudies-literature
Unknown Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
| S-EPMC7565021 | biostudies-literature
Unknown Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.
| S-EPMC3478516 | biostudies-literature